New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

A daily pill to help people newly diagnosed with type 1 diabetes, or those at risk of developing it, live without the ...

Future trial results investigating the role of ivonescimab in patients ... advisory board participation for Eli Lilly, MSD, ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

Physical function decline is an increasingly recognised concern among individuals with long-term conditions such as Type 2 ...

The Hollywood star sat down with Newsweek to discuss his next big project: upping enrollment in clinical trials.